Additional treatment can be given after surgery to reduce the chance of the cancer coming back. These are called adjuvant treatments. However, recent clinical trials of adjuvant treatment using targeted therapies such as sunitinib, sorafenib and pazopanib have failed to show a benefit for patients and have not helped to stop the cancer from coming back. Clinical trials are ongoing to see if immunotherapies can act as adjuvant treatment after surgery to reduce the chance of the cancer recurring.